About
Veana Therapeutics is a privately-held clinical stage, research and development biotechnology company whose primary mission is to develop safe and effective oral medicines that selectively kill cancer cells and can boost the immune response of cancer patients.
Technologies
Veana’s first-in class immunogenic mitochondrial oncotherapy (“VIMO”) consists of oral medicines that selectively destabilize and destroy tumor cell mitochondria to induce apoptosis and cancer-cell specific immunogenic cell death for the safe and effective treatment of a wide variety of cancers.
Veana’s flagship product VT-101 is a proprietary oral salt formulation of alpha-TEA (alpha-tocopheryloxyacetic acid) optimized for cancer-specific, mitochondrial mediated immunogenic cell death and is highly complementary to checkpoint blockade and other targeted therapies.
“Veana Therapeutics’ mission is to develop effective and safer oral cancer medicines that will improve and extend the lives of the many people who are affected by the deadly disease of cancer”
